ELK1 and myeloid leukemia: Given that upregulation of ELK1 will convert erythroid potential CMP into myeloid potential and knocking down of ELK1 only blocks neutrophil without affect erythroid differentiation, we believe that ELK1 could be an important target for therapies that treat myeloid leukemia.